Deborah Ann  Miller net worth and biography

Deborah Miller Biography and Net Worth

insider of Nuvalent

Deborah (Deb) Miller, Ph.D., J.D., joined Nuvalent as Chief Legal Officer in June 2021 and is responsible for legal and human resources. She brings more than 20 years of senior leadership and global legal expertise across the entire pharmaceutical lifecycle from early discovery though litigation.

Prior to joining Nuvalent, she most recently served as Senior Vice President, Deputy General Counsel and Chief IP Counsel for Sumitomo Dainippon Pharma America (SDPA), a shared services company supporting affiliates of the Sumitomo Dainippon Pharma Group including Sunovion Pharmaceuticals Inc. and SDP Oncology. At SDPA, she led global IP strategy, IP diligence, as well as various contract dispute matters and business development transactions and was instrumental in building and enforcing global IP portfolios for over 30 oncologic, neurologic, psychiatric, and respiratory products, including LATUDA®, KYNMOBI®, APTIOM®, and LONHALA® MAGNAIR®.

Earlier in her career, Deb served as Deputy General Counsel and Chief Patent Counsel at Infinity Pharmaceuticals where she was responsible for developing the IP strategy of various oncology products and helped secure multiple strategic partnerships. In addition, she served as Corporate Counsel at Sepracor (now Sunovion) where she managed the litigation of LUNESTA® and developed the IP for various CNS and respiratory products. She began her legal career in private practice at Nutter McClennen & Fish.

Deb earned her Bachelor’s degree in chemistry from Swarthmore College, Master’s in Medical Sciences from Harvard Medical School, Ph.D. in biological chemistry and molecular pharmacology from Harvard University, and J.D. from Suffolk University Law School.

What is Deborah Ann Miller's net worth?

The estimated net worth of Deborah Ann Miller is at least $3.49 million as of September 9th, 2024. Dr. Miller owns 33,300 shares of Nuvalent stock worth more than $3,494,169 as of October 6th. This net worth evaluation does not reflect any other assets that Dr. Miller may own. Additionally, Dr. Miller receives a salary of $595,960.00 as insider at Nuvalent. Learn More about Deborah Ann Miller's net worth.

How old is Deborah Ann Miller?

Dr. Miller is currently 48 years old. There are 4 older executives and no younger executives at Nuvalent. The oldest executive at Nuvalent is Prof. Matthew D. Shair Ph.D., Founder, Head of Scientific Advisory Board & Director, who is 55 years old. Learn More on Deborah Ann Miller's age.

What is Deborah Ann Miller's salary?

As the insider of Nuvalent, Inc., Dr. Miller earns $595,960.00 per year. There are 3 executives that earn more than Dr. Miller. The highest earning executive at Nuvalent is Dr. James R. Porter Ph.D., CEO, President & Director, who commands a salary of $1,050,000.00 per year. Learn More on Deborah Ann Miller's salary.

How do I contact Deborah Ann Miller?

The corporate mailing address for Dr. Miller and other Nuvalent executives is , , . Nuvalent can also be reached via phone at 857-357-7000 and via email at [email protected]. Learn More on Deborah Ann Miller's contact information.

Has Deborah Ann Miller been buying or selling shares of Nuvalent?

Deborah Ann Miller has not been actively trading shares of Nuvalent over the course of the past ninety days. Most recently, Deborah Ann Miller sold 3,000 shares of the business's stock in a transaction on Monday, September 9th. The shares were sold at an average price of $88.18, for a transaction totalling $264,540.00. Following the completion of the sale, the insider now directly owns 33,300 shares of the company's stock, valued at $2,936,394. Learn More on Deborah Ann Miller's trading history.

Who are Nuvalent's active insiders?

Nuvalent's insider roster includes Alexandra Balcom (CFO), Emily Conley (Director), Andrew Hack (Director), Deborah Miller (insider), Darlene Noci (insider), Henry Pelish (Insider), Matthew Shair (Director), and Christopher Turner (Insider). Learn More on Nuvalent's active insiders.

Are insiders buying or selling shares of Nuvalent?

During the last year, insiders at the sold shares 43 times. They sold a total of 1,631,129 shares worth more than $118,324,365.90. The most recent insider tranaction occured on October, 1st when insider Darlene Noci sold 5,000 shares worth more than $508,700.00. Insiders at Nuvalent own 12.5% of the company. Learn More about insider trades at Nuvalent.

Information on this page was last updated on 10/1/2024.

Deborah Ann Miller Insider Trading History at Nuvalent

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/9/2024Sell3,000$88.18$264,540.0033,300View SEC Filing Icon  
8/8/2024Sell3,000$68.78$206,340.0033,300View SEC Filing Icon  
7/12/2024Sell6,000$80.16$480,960.0033,300View SEC Filing Icon  
7/8/2024Sell3,000$73.23$219,690.0033,300View SEC Filing Icon  
5/2/2024Sell3,000$72.07$216,210.0033,300View SEC Filing Icon  
4/4/2024Sell3,000$73.60$220,800.0033,300View SEC Filing Icon  
3/28/2024Sell22,000$75.20$1,654,400.0033,300View SEC Filing Icon  
9/15/2023Sell2,000$47.64$95,280.00View SEC Filing Icon  
7/17/2023Sell2,000$43.06$86,120.00View SEC Filing Icon  
5/15/2023Sell2,000$40.74$81,480.00View SEC Filing Icon  
5/9/2023Sell1,332$39.63$52,787.16View SEC Filing Icon  
5/5/2023Sell2,800$39.64$110,992.00View SEC Filing Icon  
4/17/2023Sell2,000$30.10$60,200.00View SEC Filing Icon  
1/17/2023Sell2,000$32.62$65,240.00View SEC Filing Icon  
12/15/2022Sell2,000$29.98$59,960.00View SEC Filing Icon  
11/15/2022Sell2,000$31.91$63,820.00View SEC Filing Icon  
See Full Table

Deborah Ann Miller Buying and Selling Activity at Nuvalent

This chart shows Deborah Ann Miller's buying and selling at Nuvalent by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Nuvalent Company Overview

Nuvalent logo
Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $104.93
Low: $101.68
High: $105.28

50 Day Range

MA: $86.56
Low: $67.44
High: $112.17

2 Week Range

Now: $104.93
Low: $49.02
High: $113.51

Volume

308,522 shs

Average Volume

440,765 shs

Market Capitalization

$6.77 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.29